Why the study?
The 2025 ESC/EACTS guidelines expanded TAVI indications toward earlier intervention and younger patients, creating critical knowledge gaps regarding durability, complications, and reintervention.
Does transcatheter aortic valve implantation improve outcomes compared to surgical aortic valve replacement across all risk categories of aortic stenosis?
Design
Review
Key result
TAVI is associated with significantly lower all-cause mortality compared to SAVR in high-risk patients.
Authors
Loading...
Supports TAVI in high-risk aortic stenosis; leaves open durability and leak concerns for younger patients.
Does transcatheter aortic valve implantation improve outcomes compared to surgical aortic valve replacement across all risk categories of aortic stenosis?
Effect estimate: HR 0.55 (95% CI 0.4-0.7)
Absolute Event Rate: 30.7% vs 50.7%
p-value: p=<0.001
TAVI has evolved into a first-line therapy for aortic stenosis across all risk categories, supported by the 2025 ESC/EACTS guidelines, though long-term durability and specific complications remain critical challenges for younger patients.
Lee et al. (2026) conducted a review in Aortic Stenosis. Transcatheter aortic valve implantation (TAVI) vs. Surgical aortic valve replacement (SAVR) was evaluated on All-cause mortality (HR 0.55, 95% CI 0.4-0.7, p=<0.001). TAVI is associated with significantly lower all-cause mortality compared to SAVR in high-risk patients.